Skip to content
Research Article Open access CC BY 4.0

A Rare Incidence of Ethambutol Induced Toxic Optic Neuropathy

M. V. Mousigan, L. Nissi, V. Sreenivasan

International Journal of Medical and Pharmaceutical Case Reports · pp. 1–5 · Published 2 Jan 2023

10.9734/ijmpcr/2023/v16i1322

Abstract

Ethambutol induces toxic optic neuropathy (EON), which most typically presents as bilateral symmetrical loss of vision and, due to a lack of early detection and adequate treatment, often causes serious irreversible visual impairment. EON is time and dose dependent. In this case report, we will discuss a 59-year-old female patient who came in with complaints of visual impairment, inclusive of a colour vision defect (dyschromatopsia) and blurred vision (scotoma). Her past medication history includes use of first-line anti-tubercular therapy (ATT) with four drugs: Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide. Pyrazinamide was taken for two months, and other medications (Rifampicin, Isoniazid, and Ethambutol) were taken for a period of seven months. From this case report, we will get a clear picture necessitating continuous monitoring for ocular toxicity.

Ethambutol-induced Optic Neuropathy (EON) Anti-Tubercular Therapy (ATT) reversible Duration and dose dependent

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.